Filing Details

Accession Number:
0001827672-23-000020
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-21 19:01:10
Reporting Period:
2023-03-17
Accepted Time:
2023-03-21 19:01:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1819790 Tarsus Pharmaceuticals Inc. TARS Biological Products, (No Disgnostic Substances) (2836) 814717861
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1827672 R. Bobak Azamian C/O Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road, Suite 160
Irvine CA 92618
President/Ceo And Board Chair Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-03-17 795 $13.28 11,463 No 4 S Direct
Common Stock Disposition 2023-03-20 741 $12.61 10,722 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,080,536 Indirect By the Bobak Azamian Living Trust, established April 16, 2018
Footnotes
  1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  2. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.